title: [Analysis of Therapy and Efficacy after Remission of Acute Myeloid Leukemia].
abstract: OBJECTIVE
  To investigate the therapy and efficacy after remission of patients with acute myeloid leukemia (AML).
  
  
  METHODS
  The clinical data of 110 patients diagnosed as AML treated from 2008 to 2013 were analyzed retrospectively. According to different consolidation therapy regimens, the patients were divided into 4 groups:1 ID-Ara-C group, 2 ID-Ara-C group, 3-4 ID-Ara-C group, allogeneic hematopoietic stem cell transplantation (allo-HSCT) group. The disease-free survival (DFS) and overall survival (OS) were analyzed retrospectovely.
  
  
  RESULTS
  110 patients were completely remittend by 1-2 couses. The median follow-up time was 26.8 months, 35 cases relapsed and 58 cases died, the median DFS and OS were 20.5 and 26.8 months. The 3-year DFS of 1, 2, 3-4 ID-Ara-C and allo-HSCT groups were 0%, 36.1%, 37.5% and 67.9% respectively. The 5-year DFS of 1, 2, 3-4 ID-Ara-C and allo-HSCT groups were 0%, 30.1%, 37.5% and 63.0%. The 3-year OS rates of 1, 2 ID-Ara-C groups, 3-4 ID-Ara-C group and allo-HSCT group were 24.0%, 36.0%, 58.3% and 67.8%. The 5-year OS of 1, 2 ID-Ara-C grous, 3-4 ID-Ara-C and allo-HSCT group were 24.0%, 36.0%, 58.3% and 67.8% respectively. The 5-year OS rates of 1 ID-Ara-C group, 2 ID-Ara-C group, 3-4 ID-Ara-C group were 0%,30.0%,35.0% and 62.9% respectively. The multifactor analysis indicated that the courses of ID-Ara-C and allo-HSCT were independent risk factors for DFS and OS.
  
  
  CONCLUSIONS
  ≥2 ID-Ara-C regimen may be used as one regimen of consolidation therapy for patients with AML after remission.
authors.affiliation: Department of Hematology,The First Affiliated Hospital,Xin jiang Medical University,Urumqi 830054, Xinjiang Uygur Autonomous Region, China.
authors.forename: Shu-Yi
authors.initials: SY
authors.lastname: Zhao
authors.affiliation: Department of Hematology,The First Affiliated Hospital,Xin jiang Medical University,Urumqi 830054, Xinjiang Uygur Autonomous Region, China.
authors.forename: Nilupar
authors.initials: N
authors.lastname: Tuerxun
authors.affiliation: Department of Hematology,The First Affiliated Hospital,Xin jiang Medical University,Urumqi 830054, Xinjiang Uygur Autonomous Region, China.
authors.forename: Rong
authors.initials: R
authors.lastname: Chen
authors.affiliation: Department of Hematology,The First Affiliated Hospital,Xin jiang Medical University,Urumqi 830054, Xinjiang Uygur Autonomous Region, China. E-mail:417745192@qq.com.
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Hao
mesh_terms: D003561:Cytarabine; D018572:Disease-Free Survival; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute; D012074:Remission Induction; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
chemical_list: D003561:Cytarabine